Skip to main content
Explore URMC

menu

Colorectal Cancer: Regorafenib in Adults ≥ 70 Years with Metastatic Colorectal Cancer

Research Question:
How does the drug regorafenib effect quality of life and other issues relevant to the elderly when given to adults age 70 or older to treat their colorectal cancer?

Basic Study Information

Purpose:
The standard treatment for metastatic colorectal cancer usually includes chemotherapy which can have side effects that are more difficult to tolerate for older patients with cancer. Regorafenib (a non-chemotherapy option) was recently approved by the FDA for treatment of patients whose cancer had grown on all standard chemotherapy agents. This study is being done among elderly patients, whose cancer has grown on all chemotherapy agents or who are not able to tolerate chemotherapy, to measure the safety of regorafenib in the elderly population and to assess how well the drug controls cancer growth.

Location: cancer center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02466009?term=02466009&rank=1
Study Reference #: UGIC-14072

Lead Researcher (Principal Investigator)

Lead Researcher: Mohamedtaki Tejani, MD

Study Contact Information

Study Coordinator: Tanya Smith
Phone: (585) 275-8213
Email: Tanya_Smith@urmc.rochester.edu

Additional Study Details

Return to Search